-
Traditional Chinese medicine is ushering in a broad space for development, and the status of decocting machine is becoming more and more prominent
Time of Update: 2021-11-14
Therefore, in terms of automation and information technology improvement of the decocting machine, the industry still needs to make continuous efforts to better contribute to the sustainable development of traditional Chinese medicine .
-
Digital technology + pharmaceutical equipment, or open up a broader market space
Time of Update: 2021-11-14
The industry pointed out that digital technology + pharmaceutical equipment will help companies open up a broader market space .
As more and more pharmaceutical machinery companies gradually transform and upgrade from traditional single equipment suppliers to system integrators and solution providers, they will bring more benefits to customers and create greater value .
-
Yantai: This is how the blueprint of the biomedical industry will be described!
Time of Update: 2021-11-14
In accordance with the layout principle of “coordinated linkage, intensive clustering, and characteristic development”, Yantai City will build a “1+3+X” biomedical industry spatial layout, namely, to create a life science innovation leading core area in the east, a high-end medical equipment cluster development area in the west, and a central area.
-
FDA approves multiple investigational new drug applications
Time of Update: 2021-11-14
” Theseus intends to initiate a phase I/II dose escalation and expansion clinical trial, which will include For patients with advanced GIST who have previously received treatment, the study is expected to start at the end of the fourth quarter of 2021 or the first quarter of 2022 .
-
Announcement of the National Medical Products Administration on the addition of children's drug information to the instructions for haloperidol tablets and other varieties (No. 75 of 2021)
Time of Update: 2021-11-14
Recommendations for revisions to drug inserts of fluoxetine oral preparations National Food and Drug Administration May 28, 2021 Announcement No.
-
The three major problems in the industry with the general price rise of Chinese herbal medicines are coming!
Time of Update: 2021-11-14
So, in the use of terminal demand is not prosperous, but the source of the production end is a growing boom in planting, and the supply of goods will continue to emerge in the future, and the market prices of many Chinese medicinal materials will always be as they are now.
-
Announcement of the State Drug Administration on Protected Varieties of Traditional Chinese Medicines (Extended Protection Period No. 7) (No. 73 of 2021)
Time of Update: 2021-11-14
According to Article 16 of the Regulations on the Protection of Traditional Chinese Medicines and related regulations, after review by the members organized by the National Traditional Chinese Medici
-
The R&D strength of domestic pharmaceutical companies continues to improve, and the authorized transactions of pharmaceutical companies are becoming more frequent
Time of Update: 2021-11-14
Recently, Shanghai Pharmaceuticals announced that it has reached an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China .
-
Corning Jerry appoints Han Jing as chief commercial officer
Time of Update: 2021-11-14
Han Jing has extensive commercialization experience in multinational and local pharmaceutical companies, and has led the team to successfully promote outstanding innovative drugs to The market benefits the majority of patients .
-
Pharmaceutical companies showed strong willingness to invest in R&D, allowing R&D to be in the “C” position
Time of Update: 2021-11-14
Data shows that in the first three quarters of this year, some listed pharmaceutical companies invested more than 100 million yuan in research and development, and their share of revenue continued to increase .
In recent years, China's pharmaceutical companies have continuously increased their R&D investment.
-
Entering November, there are new changes in the executives of many pharmaceutical companies
Time of Update: 2021-11-14
Virginia Ellen Maher as the vice president of medical sciences, responsible for the strategy formulation, guidance and supervision of the company’s clinical development projects throughout the cycle, and reported to the company’s Chief Medical Officer (CMO) Patricia Dr.
-
The competitive landscape of the innovative drug industry is facing reconstruction, and FIC drugs are more favored by capital
Time of Update: 2021-11-14
Also in September, Yinming Bio, which is committed to the research and development of first-in-class drugs with global competitiveness, announced the completion of nearly US$50 million in A+ round of financing .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Propylthiouracil Preparations (No. 103 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and in accordance with the requirements for the revision of the propylthiouracil preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record .
-
Announcement of the State Drug Administration on 16 batches of drugs that do not meet the requirements (No. 36 of 2021)
Time of Update: 2021-11-14
After inspection by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute, 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
-
Announcement of the State Drug Administration on 18 batches of drugs that do not meet the requirements (No. 59 of 2021)
Time of Update: 2021-11-14
After inspection by Hubei Provincial Institute of Drug Supervision and Inspection, a batch of Atractylodes japonicus (fried atractylodes with bran) produced by Anhui Wukeng Chinese Medicine Decoction Pieces Co.
-
Boehringer Ingelheim announced that the European Medicines Agency has accepted and reviewed the marketing authorization application for spesolimab for the treatment of generalized pustular psoriasis
Time of Update: 2021-11-14
"GPP is a rare and life-threatening neutrophil skin disease characterized by the sudden appearance of sterile, pus-filled blisters and painful sensations all over the body," said Janine, Boehringer Ingelheim Global Head of Spesolimab Lamar said .
[6],[7]About generalized pustular psoriasisGPP is a rare, heterogeneous, and life-threatening neutrophilic skin disease, which is clinically different from plaque psoriasis .
-
The first domestic product! Connoa's MASP-2 monoclonal antibody was approved for clinical use
Time of Update: 2021-11-14
CM338 is the first domestic innovative monoclonal antibody drug targeting MASP-2 and the second clinically approved MASP-2 inhibitor in the world .
-
21 batches of medicines in Yunnan Province were found to be unqualified, and Chinese herbal medicines accounted for the majority
Time of Update: 2021-11-14
Subsequently, in May of the same year, the State Food and Drug Administration held a video and telephone conference, requesting drug regulatory authorities at all levels to implement territorial regulatory responsibilities in accordance with the "four strictest" requirements, carefully inspect the production and operation units of traditional Chinese medicine decoction pieces and preparations, and resolutely investigate and punish violations of the law.
-
AstraZeneca sells two COPD drugs for $270 million
Time of Update: 2021-11-14
Eklira is a long-acting muscarinic antagonist (LAMA), which was approved for marketing in the European Union and the United States in 2012 .
-
The pharmaceutical industry accelerates innovation, and these companies have invested heavily in R&D in the first three quarters
Time of Update: 2021-11-14
. It is worth mentioning that since its listing in 2003, the operating income of the State Development Corporation has not improved, and the total net profit for the 18 years of listing has been about 480 million yuan .